Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H25NO3 |
| Molecular Weight | 291.3853 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC[C@@H](O)\C=C(C)\C=C\C=C\C(=O)N1CCCC1=O
InChI
InChIKey=ZYPGADGCNXOUJP-CXVPHVKISA-N
InChI=1S/C17H25NO3/c1-3-4-9-15(19)13-14(2)8-5-6-10-16(20)18-12-7-11-17(18)21/h5-6,8,10,13,15,19H,3-4,7,9,11-12H2,1-2H3/b8-5+,10-6+,14-13+/t15-/m1/s1
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13855011 | https://www.ncbi.nlm.nih.gov/pubmed/?term=13848726
Curator's Comment: 1959
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.whocc.no/atc_ddd_index/?code=D01AA04
Curator's Comment: Dosage for use in human is unknown. Variotin (3,000 U/g ointment) was studied in a guinea pig model of tinea pedis http://www.ncbi.nlm.nih.gov/pubmed/11521512
3,000 U/g ointment (guinea pig)
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
||
|
WHO-ATC |
D01AA04
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
||
|
WHO-VATC |
QD01AA04
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000083004
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
2145
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL486174
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
243-116-9
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
C72593
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
5282176
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
SUB09643MIG
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
3419
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
PECILOCIN
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
m8438
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
19504-77-9
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
TSA7W27MF8
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
DB13459
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
C001405
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
291839
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY | |||
|
DTXSID5057676
Created by
admin on Mon Mar 31 18:05:16 GMT 2025 , Edited by admin on Mon Mar 31 18:05:16 GMT 2025
|
PRIMARY |
ACTIVE MOIETY